In ALS, the measures of motor function and survival are important to confirm proof of concept (POC). If we confirm the functional recovery by the protection of upper motor neuron (UMN), we could proceed the drug development.
|Effective start/end date||12/19/19 → 3/31/21|
- Mitsubishi Tanabe Pharma Holdings America, Inc. (Agmt 12/19/19)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.